<DOC>
	<DOCNO>NCT01954927</DOCNO>
	<brief_summary>This phase II double-blind placebo-controlled clinical trial evaluate effect gabapentin add standard pain management patient sickle cell disease experience acute pain crisis ambulatory care set . Sickle cell pain different every patient . Some patient get complete relief routine pain medicine , others need time dos pain medicine pain go away completely . It know human many type pain , include something call neuropathic pain . Neuropathic pain condition ( diabetes ) treat successfully medicine call gabapentin . The investigator study suspect sickle cell pain combination pain type . They would like see add gabapentin usual pain medicine make pain go away faster completely . Primary Objective : - To assess analgesic efficacy gabapentin vs. placebo pain vaso-occlusive crisis ( VOC ) participant sickle cell disease ( SCD ) . A response study drug define decrease pain score ≥ 33 % presentation acute care set assessment 3 hour post administration study drug . Secondary Objective : - To compare total morphine equivalent dose ( mg/kg ) use control pain VOC presentation acute care set assessment 3 hour post administration study drug gabapentin vs. placebo group .</brief_summary>
	<brief_title>Pain Management Children Young Adults With Sickle Cell Disease</brief_title>
	<detailed_description>Upon participant enrollment , study staff randomize participant one 2 possible treatment arm : single dose gabapentin single dose placebo . Morphine opioid non-steroidal anti-inflammatory drug available group need pain administer accord current standard care pain VOC Department Hematology St. Jude Children 's Research Hospital ( SJCRH ) . Randomization perform SJCRH pharmacy pharmacist . The randomization stratify three age category ( 1-3 year age , 4-6 year , 7 year old ) distinct pain assessment tool apply 2 pain score category assessment presentation ( 4-6 7-10 , respectively ) . A block randomization block size vary randomly 4 6 use stratum . Pain score obtain presentation acute care set 3 hour ( ± 15 minute ) post administration study drug . Participants discharge contact study staff 24 72 hour follow administration study drug see side effect . Patients admitted administration study drug monitor hospital record determine unexpected event occur . After follow , participation study complete .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Participant must sickle cell disease ( genotype ) document St. Jude medical record . Participant must seek care acute vasoocclusive pain St. Jude Children 's Research Hospital . Participant age must ≥1 year &lt; 21 year . Prior randomization study . Mild pain ( score &lt; 4 ) pain treatment opioid indicate . Pregnant lactate female . Decreased glomerular filtration rate ( GFT ) ( &lt; 60ml/min/1.73m^2 ) estimate revise Schwartz equation . Current treatment gabapentinoid drug ( gabapentin pregabalin ) . Known seizure disorder . Current treatment antiepileptic agent . Pain combination clinical symptom require additional intervention , include fever focus , acute chest syndrome , acute injury , splenic sequestration . Allergy gabapentin . Current participation another research study investigational new drug/device ( IND/IDE ) agent . Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pain control</keyword>
</DOC>